
Uvan Pharmaceuticals Private Limited
About Uvan Pharmaceuticals Private Limited
Data last updated:
Uvan Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the artificial fibres segment of the food and beverages sector. It was incorporated on 16 March 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24304DL2018PTC331041.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹50 Lakh. It is led by directors Manoj Paliwal and Yash Mehra Mohan.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at House No 635 Kh. No. 484/179 Ground Floor Village Sindhora Kalan Blk – A Shastri Nag, Ar City, Delhi, India – 110052.
As per the financials filed for FY 2025, the company reported a revenue of ₹98.27 Lakh, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹31.04 Lakh (net margin 31.6%) and EBITDA of ₹42.29 Lakh (EBITDA margin 43%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 28% over five years.
The company has 1 deal on record (1 rights issue); the latest was in October 2021.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Uvan Pharmaceuticals Private Limited's registered office is in Delhi, Delhi.
- Registered AddressHouse No 635 Kh. No. 484/179 Ground Floor Village Sindhora Kalan Blk – A Shastri Nag, Ar City, Delhi, India – 110052
- IndustryFood And Beverages, Artificial Fibres, Manufacturing
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Uvan Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Uvan Pharmaceuticals Private Limited, buy the company report.
Financials of Uvan Pharmaceuticals Private Limited
FY 2025 filings availableUvan Pharmaceuticals Private Limited reported revenue of ₹98.27 Lakh (down 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 2% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 28%. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹42.29 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹31.04 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 43% | ||||
| Net Profit Margin | 31.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Uvan Pharmaceuticals Private Limited, buy the company report.
Board of directors of Uvan Pharmaceuticals Private Limited
Uvan Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manoj Paliwal Also directs: Indimonk Remedies Private Limited, Uvamonk Private Limited | Director | 09 Dec 2021 | 4 Years 10 Months | Current |
| Yash Mehra Mohan Also directs: Ulberto Pharma Private Limited, Yashved Remedies Private Limited, Indimonk Remedies Private Limited and 1 more | Director | 16 Mar 2018 | 8 Years 7 Months | Current |
Deals & funding
Uvan Pharmaceuticals Private Limited has 1 deal on record (1 rights issue); the latest was in October 2021.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2021 | Rights issue | ₹18 Lakh | Investors: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Uvan Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Uvan Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Uvan Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Uvan Pharmaceuticals Private Limited has 3 board changes on record since 2018: 2 appointments and 1 cessation. The latest: Haqiqat Handa ceased to be Director on 13 Dec 2021.
Frequently asked questions
Uvan Pharmaceuticals is an active private limited company based in Delhi, India. The company works in artificial fibres, within the food and beverages industry. It was incorporated on 16 March 2018 (8+ years old) and is registered under CIN U24304DL2018PTC331041.
Uvan Pharmaceuticals has 2 current directors:
- Manoj Paliwal - Director
- Yash Mehra Mohan - Director
The latest financial statements of Uvan Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The CIN (Corporate Identification Number) of Uvan Pharmaceuticals is U24304DL2018PTC331041. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Uvan Pharmaceuticals was incorporated on 16 March 2018, making it 8+ years old. It is registered with the Registrar of Companies, Delhi.
Uvan Pharmaceuticals has 1 deal on record (1 rights issue); the latest was in October 2021.
Haqiqat Handa ceased to be Director on 13 Dec 2021. Manoj Paliwal was appointed as Director on 09 Dec 2021. Yash Mehra Mohan was appointed as Director on 16 Mar 2018.
The registered office of Uvan Pharmaceuticals is at House No 635 Kh. No. 484179 Ground Floor Village Sindhora Kalan Blk – A Shastri Nag, Ar City, Delhi, India – 110052.
Uvan Pharmaceuticals operates in the food and beverages industry, in the artificial fibres segment.
The compliance status of Uvan Pharmaceuticals is compliant as of 14 September 2026. The company is actively filing with the Registrar of Companies.

